Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06849713 · ClinicalTrials.gov registry record · Phase 2

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

A Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (SLL), sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT06849713: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (SLL), sponsored by Massachusetts General Hospital.

NCT06849713 is a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06849713, a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma (SLL)

Interventions

  • DRUG Zanubrutinib
  • DRUG Obinutuzumab
  • DRUG Sonrotoclax

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-05-16
Est. Completion 2030-03-01
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06849713

The ClinicalTrials.gov registry entry for NCT06849713 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.

NCT06849713 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT06849713 about?

NCT06849713 is a clinical study titled "Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL". The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

What is the current status of trial NCT06849713?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-16. Estimated completion is 2030-03-01.

What conditions does trial NCT06849713 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL).

What interventions are being tested in trial NCT06849713?

The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Sonrotoclax (DRUG).

Who is sponsoring clinical trial NCT06849713?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06849713 being conducted?

This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Small Lymphocytic Lymphoma (SLL)

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.